메뉴 건너뛰기




Volumn 15, Issue 1, 2012, Pages 12-20

Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms

Author keywords

desvenlafaxine; Hot flushes; menopause; tibolone; vasomotor symptoms

Indexed keywords

DESVENLAFAXINE; PLACEBO; TIBOLONE;

EID: 84855216098     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.586445     Document Type: Article
Times cited : (33)

References (30)
  • 1
    • 73349115219 scopus 로고    scopus 로고
    • Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up
    • Barbaglia G, Macia F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-4
    • (2009) Menopause , vol.16 , pp. 1061-4
    • Barbaglia, G.1    Macia, F.2    Comas, M.3
  • 2
    • 0042018741 scopus 로고    scopus 로고
    • Breast cancer and hormone-replacement therapy in the Million Women Study
    • DOI 10.1016/S0140-6736(03)14065-2
    • Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
    • (2003) Lancet , vol.362 , Issue.9382 , pp. 419-427
    • Beral, V.1
  • 3
    • 84855248789 scopus 로고    scopus 로고
    • Estrogen and progestogen use in postmenopausal women
    • Estrogen and progestogen use in postmenopausal women: 2010
  • 4
    • 77949345161 scopus 로고    scopus 로고
    • Position statement of The North American Menopause Society
    • position statement of The North American Menopause Society. Menopause 2010;17:242-5
    • (2010) Menopause , vol.17 , pp. 242-5
  • 7
    • 67650021834 scopus 로고    scopus 로고
    • Benefi ts and risks of postmenopausal hormone therapy when it is initiated soon after menopause
    • Prentice RL, Manson JE, Langer RD, et al. Benefi ts and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23
    • (2009) Am J Epidemiol , vol.170 , pp. 12-23
    • Prentice, R.L.1    Manson, J.E.2    Langer, R.D.3
  • 8
    • 84855248787 scopus 로고    scopus 로고
    • Pristiq [package insert] Philadelphia PA Wyeth Pharmaceuticals Inc
    • Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2009
  • 9
    • 37549033111 scopus 로고    scopus 로고
    • Study 315 investigators. Effi cacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial
    • Speroff L, Gass M, Constantine G, Olivier S, Study 315 investigators. Effi cacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial. Obstet Gynecol 2008 111 77-87
    • (2008) Obstet Gynecol , vol.111 , pp. 77-87
    • Speroff, L.1    Gass, M.2    Constantine, G.3    Olivier, S.4
  • 10
    • 58749098561 scopus 로고    scopus 로고
    • A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine effi cacy and safety for the treatment of vasomotor symptoms associated with menopause
    • e1-172.e10
    • Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine effi cacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10
    • (2009) Am J Obstet Gynecol , vol.200 , pp. 172
    • Archer, D.F.1    Seidman, L.2    Constantine, G.D.3    Pickar, J.H.4    Olivier, S.5
  • 11
    • 60849107728 scopus 로고    scopus 로고
    • Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A doubleblind, randomized, placebo-controlled trial of effi cacy and safety
    • e1-238.e10
    • Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A doubleblind, randomized, placebo-controlled trial of effi cacy and safety. Am J Obstet Gynecol 2009;200:238.e1-238.e10
    • (2009) Am J Obstet Gynecol , vol.200 , pp. 238
    • Archer, D.F.1    Dupont, C.M.2    Constantine, G.D.3    Pickar, J.H.4    Olivier, S.5
  • 12
    • 13944279222 scopus 로고    scopus 로고
    • Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day
    • DOI 10.1016/j.maturitas.2004.06.001
    • Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot fl ushes and sweats per day. Maturitas 2005;50:222-30 (Pubitemid 40269905)
    • (2005) Maturitas , vol.50 , Issue.3 , pp. 222-230
    • Landgren, M.B.1    Helmond, F.A.2    Engelen, S.3
  • 13
    • 0036146189 scopus 로고    scopus 로고
    • Tibolone for postmenopausal women: Systematic review of randomized trials
    • DOI 10.1210/jc.87.1.16
    • Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23 (Pubitemid 34084663)
    • (2002) Journal of Clinical Endocrinology and Metabolism , vol.87 , Issue.1 , pp. 16-23
    • Modelska, K.1    Cummings, S.2
  • 14
    • 58749098915 scopus 로고    scopus 로고
    • Safety and effi cacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial
    • Kenemans P, Bundred NJ, Foidart JM, et al. Safety and effi cacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-46
    • (2009) Lancet Oncol , vol.10 , pp. 135-46
    • Kenemans, P.1    Bundred, N.J.2    Foidart, J.M.3
  • 15
    • 84855217832 scopus 로고    scopus 로고
    • European Medicines Agency Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Defi ciency Symptoms in Postmenopausal Women European Medicines Agency, 1-11. 10-13-2005
    • European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Defi ciency Symptoms in Postmenopausal Women. European Medicines Agency, 1-11. 10-13-2005
  • 16
    • 84855237363 scopus 로고    scopus 로고
    • Food and Drug Administration U.S. Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry-Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation
    • Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry-Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation, 2003
  • 18
    • 0032550785 scopus 로고    scopus 로고
    • Constructing a standard climacteric scale
    • DOI 10.1016/S0378-5122(98)00025-5, PII S0378512298000255
    • Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31 (Pubitemid 28247565)
    • (1998) Maturitas , vol.29 , Issue.1 , pp. 25-31
    • Greene, J.G.1
  • 19
    • 0036227699 scopus 로고    scopus 로고
    • A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: Effects on symptom control, bleeding pattern, lipid profile and tolerability
    • Baracat EC, Barbosa IC, Giordano MG , et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: Effects on symptom control, bleeding pattern, lipid profi le and tolerability. Climacteric 2002; 5:60-9 (Pubitemid 34309856)
    • (2002) Climacteric , vol.5 , Issue.1 , pp. 60-69
    • Baracat, E.C.1    Barbosa, I.C.2    Giordano, M.G.3    Haidar, M.A.4    Marinho, R.M.5    Menegocci, J.C.6    Morais, K.M.7    Tomaz, G.8    Wehba, S.9
  • 20
    • 0037171959 scopus 로고    scopus 로고
    • Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus
    • DOI 10.1016/S0378-5122(01)00298-5, PII S0378512201002985
    • Mendoza N, Pison JA, Fernandez M, et al. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289-98 (Pubitemid 34603398)
    • (2002) Maturitas , vol.41 , Issue.4 , pp. 289-298
    • Mendoza, N.1    Pison, J.A.2    Fernandez, M.3    Sanchez, M.C.4    Malde, J.5    Miranda, J.A.6
  • 23
    • 31344471005 scopus 로고    scopus 로고
    • Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects
    • DOI 10.1001/archinte.166.2.155
    • Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects. Arch Intern Med 2006;166:155-60 (Pubitemid 43144937)
    • (2006) Archives of Internal Medicine , vol.166 , Issue.2 , pp. 155-160
    • Rief, W.1    Avorn, J.2    Barsky, A.J.3
  • 24
    • 62149130086 scopus 로고    scopus 로고
    • Gender and the nocebo response following conditioning and expectancy
    • Klosterhalfen S, Kellermann S, Braun S, et al. Gender and the nocebo response following conditioning and expectancy. J Psychosom Res 2009;66:323-8
    • (2009) J Psychosom Res , vol.66 , pp. 323-8
    • Klosterhalfen, S.1    Kellermann, S.2    Braun, S.3
  • 25
    • 34248580770 scopus 로고    scopus 로고
    • Prevalence of hot flushes and night sweats around the world: A systematic review
    • DOI 10.1080/13697130601181486, PII 778336742
    • Freeman EW, Sherif K. Prevalence of hot fl ushes and night sweats around the world: A systematic review. Climacteric 2007;10:197-214 (Pubitemid 46752443)
    • (2007) Climacteric , vol.10 , Issue.3 , pp. 197-214
    • Freeman, E.W.1    Sherif, K.2
  • 26
    • 70350596476 scopus 로고    scopus 로고
    • Non-hormonal treatment of hot fl ushes in breast cancer survivors: Gabapentin vs. vitamin E
    • Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot fl ushes in breast cancer survivors: Gabapentin vs. vitamin E. Climacteric 2009;12:310-18
    • (2009) Climacteric , vol.12 , pp. 310-18
    • Biglia, N.1    Sgandurra, P.2    Peano, E.3
  • 27
    • 73249150089 scopus 로고    scopus 로고
    • Safety and effi cacy of black cohosh and red clover for the management of vasomotor symptoms: A randomized controlled trial
    • Geller SE, Shulman LP, van Breemen RB , et al. Safety and effi cacy of black cohosh and red clover for the management of vasomotor symptoms: A randomized controlled trial. Menopause 2009; 16:1156-66
    • (2009) Menopause , vol.16 , pp. 1156-66
    • Geller, S.E.1    Shulman, L.P.2    Van Breemen, R.B.3
  • 28
    • 77949390613 scopus 로고    scopus 로고
    • Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: A double-blind, placebo-controlled study
    • Garcia JT, Gonzaga F, Tan D , et al. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: A double-blind, placebo-controlled study. Menopause 2010;17:303-8
    • (2010) Menopause , vol.17 , pp. 303-8
    • Garcia, J.T.1    Gonzaga, F.2    Tan, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.